Share This Article:

REGγ Mediated Regulation of p21Waf/Cip1, p16INK4a and p14ARF/p19ARF in Vivo

Abstract Full-Text HTML XML Download Download as PDF (Size:5080KB) PP. 933-938
DOI: 10.4236/jct.2013.45104    3,772 Downloads   6,278 Views   Citations

ABSTRACT

p21Waf/Cip1, p16INK4a and p14ARF (p19ARF in mice) have been demonstrated to be degraded by REGγ-proteasome pathway in an ATP- and ubiquitin-independent manner in vitro. However, the in vivo roles of REGγ mediated-degradation of p21Waf/Cip1, p16INK4a and p14ARF remain unclear. In this study, we showed enhanced expression of p21Waf/Cip1, p16INK4a and p19ARF in multiple tissues from REGg–/– mice compared to REGg+/+ mice. Furthermore, we examined the expression of p21Waf/Cip1, p16INK4a and p14ARF in different cancer tissues and observed that the REGγ protein levels were highly expressed in different human cancers while the level of p21Waf/Cip1, p16INK4a and p14ARF appears to be inversely correlated. These results demonstrate that REGγ may exert its function in physiological and pathological conditions through degradation of p21Waf/Cip1, p16INK4a and p14ARF in vivo.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

L. Li, P. Zhang, H. Wei, W. Wang, L. Yao, Y. Li, L. Zhou, Z. Wang, J. Liu, L. Zhou, A. Amjad, B. Zhang, T. Jing, J. Xiao, Y. Dang and X. Li, "REGγ Mediated Regulation of p21Waf/Cip1, p16INK4a and p14ARF/p19ARF in Vivo," Journal of Cancer Therapy, Vol. 4 No. 5, 2013, pp. 933-938. doi: 10.4236/jct.2013.45104.

References

[1] D. E. Quelle, F. Zindy, R. A. Ashmun, et al., “Alternative Reading Frames of the INK4a Tumor Suppressor Gene Encode Two Unrelated Proteins Capable of Inducing Cell Cycle Arrest,” Cell, Vol. 83, No. 6, 1995, pp. 993-1000. doi:10.1016/0092-8674(95)90214-7
[2] S. W. Lowe and C. J. Sherr, “Tumor Suppression by INK4a-Arf: Progress and Puzzles,” Current Opinion in Genetics & Development, Vol. 13, No. 1, 2003, pp. 77-83. doi:10.1016/S0959-437X(02)00013-8
[3] M. Serrano, H. Lee, L. Chin, et al., “Role of the INK4a Locus in Tumor Suppression and Cell Mortality,” Cell, Vol. 85, No. 1, 1996, pp. 27-37. doi:10.1016/S0092-8674(00)81079-X
[4] P. Krimpenfort, K. C. Quon, W. J. Mooi, et al., “Loss of p16INK4a Confers Susceptibility to Metastatic Melanoma in Mice,” Nature, Vol. 413, No. 6851, 2001, pp. 83-86. doi:10.1038/35092584
[5] M. Serrano, G. J. Hannon and D. Beach, “A New Regulatory Motif in Cell-Cycle Control Causing Specific Inhibition of Cyclin D/CDK4,” Nature, Vol. 366, No. 6456, 1993, pp. 704-707. doi:10.1038/366704a0
[6] C. J. Sherr, “Principles of Tumor Suppression,” Cell, Vol. 116, No. 2, 2004, pp. 235-246. doi:10.1016/S0092-8674(03)01075-4
[7] E. Sharpless and L. Chin, “The INK4a/ARF Locus and Melanoma,” Oncogene, Vol. 22, No. 20, 2003, pp. 3092-3098. doi:10.1038/sj.onc.1206461
[8] R. Ben-Saadon, I. Fajerman, T. Ziv, et al., “The Tumor Suppressor Protein p16INK4a and the Human Papillomavirus Oncoprotein-58 E7 Are Naturally Occurring LysineLess Proteins That Are Degraded by the Ubiquitin System. Direct Evidence for Ubiquitination at the N-Terminal Residue,” The Journal of Biological Chemistry, Vol. 279, No. 40, 2004, pp. 41414-41421. doi:10.1074/jbc.M407201200
[9] S. Bates, A. C. Phillips, P. A. Clark, et al., “p14ARF Links the Tumour Suppressors RB and p53,” Nature, Vol. 395, No. 6698, 1998, pp. 124-125. doi:10.1038/25867
[10] I. Palmero, C. Pantoja and M. Serrano, “p19ARF Links the Tumour Suppressor p53 to Ras,” Nature, Vol. 395, No. 6698, 1998, pp. 125-126. doi:10.1038/25870
[11] A. Radfar, I. Unnikrishnan, H. W. Lee, et al., “p19ARF Induces p53-Dependent Apoptosis during Abelson VirusMediated Pre-B Cell Transformation,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, No. 22, 1998, pp. 13194-13199. doi:10.1073/pnas.95.22.13194
[12] F. Zindy, R. T. Williams, T. A. Baudino, et al., “ARF Tumor Suppressor Promoter Monitors Latent Oncogenic Signals in Vivo,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, No. 26, 2003, pp. 15930-15935. doi:10.1073/pnas.2536808100
[13] R. Honda, and H. Yasuda, “Association of p19ARF with Mdm2 Inhibits Ubiquitin Ligase Activity of Mdm2 for Tumor Suppressor p53,” The EMBO Journal, Vol. 18, No. 1, 1999, pp. 22-27. doi:10.1093/emboj/18.1.22
[14] C. A. Midgley, J. M. Desterro, M. K. Saville, et al., “An N-Terminal p14 ARF Peptide Blocks Mdm2-Dependent Ubiquitination in Vitro and Can Activate p53 in Vivo,” Oncogene, Vol. 19, No. 19, 2000, pp. 2312-2323.
[15] X. Li, D. M. Lonard, S. Y. Jung, et al., “The SRC-3/AIB1 Coactivator Is Degraded in a Ubiquitinand ATP-Independent Manner by the REGγ Proteasome,” Cell, Vol. 124, No. 2, 2006, pp. 381-392. doi:10.1016/j.cell.2005.11.037
[16] X. Chen, L. F. Barton, Y. Chi, et al., “Ubiquitin-Independent Degradation of Cell-Cycle Inhibitors by the REGγ Proteasome,” Molecular Cell, Vol. 26, No. 6, 2007, pp. 843-852. doi:10.1016/j.molcel.2007.05.022
[17] X. Li, L. Amazit, W. Long, et al., “Ubiquitinand ATPIndependent Proteolytic Turnover of p21 by the REGgamma-Proteasome Pathway,” Molecular Cell, Vol. 26, No. 6, 2007, pp. 831-842. doi:10.1016/j.molcel.2007.05.028
[18] T. Okamura, S. Taniguchi, T. Ohkura, et al., “Abnormally High Expression of Proteasome Activator-Gamma in Thyroid Neoplasm,” The Journal of Clinical Endocrinology & Metabolism, Vol. 88, No. 3, 2003, pp. 1374-1383.
[19] M. Roessler, W. Rollinger, L. Mantovani-Endl, et al., “Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-Dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-Based Approach for Data Analysis,” Molecular & Cellular Proteomics, Vol. 5, No. 11, 2006, pp. 2092-2101. doi:10.1074/mcp.M600118-MCP200
[20] Y. Hong, K. S. Ho, K. W. Eu, et al., “A Susceptibility Gene Set for Early Onset Colorectal Cancer That Integrates Diverse Signaling Pathways: Implication for Tumorigenesis,” Clinical Cancer Research, Vol. 13, No. 4, 2007, pp. 1107-1114. doi:10.1158/1078-0432.CCR-06-1633
[21] H. L. Jia, Q. H. Ye, L. X. Qin, et al., “Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma,” Clinical Cancer Research, Vol. 13, No. 4, 2007, pp. 1133-1139. doi:10.1158/1078-0432.CCR-06-1025
[22] J. He, L. Cui, Y. Zeng, et al., “REGγ Is Associated with Multiple Oncogenic Pathways in Human Cancers,” BMC Cancer, Vol. 12, 2012, p. 75. doi:10.1186/1471-2407-12-75
[23] G. Yu, Y. Zhao, J. He, et al., “Comparative Analysis of REGγ Expression in Mouse and Human Tissues,” Journal of Molecular Cell Biology, Vol. 2, No. 4, 2010, pp. 192-198. doi:10.1093/jmcb/mjq009
[24] G. Salvatore, T. C. Nappi, P. Salerno, et al., “A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma,” Cancer Research, Vol. 67, No. 21, 2007, pp. 10148-10158. doi:10.1158/0008-5472.CAN-07-1887
[25] Y. Zhang, Y. Xiong and W. G. Yarbrough, “ARF Promotes MDM2 Degradation and Stabilizes p53: ARFINK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways,” Cell, Vol. 92, No. 6, 1998, pp. 725-734. doi:10.1016/S0092-8674(00)81401-4
[26] L. F. Barton, H. A. Runnels, T. D. Schell, et al., “Immune Defects in 28-kDa Proteasome Activator Gamma-Deficient Mice,” The Journal of Immunology, Vol. 172, No. 6, 2004, pp. 3948-3954.
[27] I. Mao, J. Liu, X. Li, et al., “REGγ, a Proteasome Activator and beyond?” Cellular and Molecular Life Sciences, Vol. 65, No. 24, 2008, pp. 3971-3980. doi:10.1007/s00018-008-8291-z
[28] Z. Zhang and R. Zhang, “Proteasome Activator PA28 Gamma Regulates p53 by Enhancing Its MDM2-Mediated Degradation,” The EMBO Journal, Vol. 27, No. 6, 2008, pp. 852-864. doi:10.1038/emboj.2008.25

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.